Back to NVSView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
View Full LandscapeDrug Information
Target Indication
Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
Clinical Trial
NCT02132130Last updated: 2/12/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Peg-alpha interferon (Peg-Intron)Phase 3
Leukemia, Myeloid, Chronic
cyclosporin + mycophenolate mofetilPhase 3
Kidney Failure
Imatinib Mesylate (Gleevec)Phase 3
Idiopathic Pulmonary Fibrosis
GP2017 (adalimumab biosimilar)Phase 3
Ankylosing Spondylitis
Nilotinib (Tasigna ®)Phase 3
Chronic Myeloid Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts